CARLSBAD, Calif.--(BUSINESS WIRE)--Invitrogen Corporation (NASDAQ:IVGN), a provider of technologies for research, production and diagnostics, has introduced its custom PD-Direct® Bioprocess Services optimized for clinically compliant stem cell culture systems. This service will help stem cell therapy developers reduce risks through serum-free production systems, improve manufacturing productivity, and provide on-demand expertise in stem cell media development.
